Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Gets “Interactive” In New Premarket Guidance Document

This article was originally published in The Gray Sheet

Executive Summary

A Dec. 28 final FDA guidance document lays out a path for more informal interaction between agency reviewers and device companies while preserving CDRH's options to place holds on premarket reviews

You may also be interested in...



510(k) Sponsors Should Be Wary Of Informal Talk With FDA, Attorney Says

Informal communications via telephone or e-mail before or during a 510(k) submission can be an efficient approach for sponsors, but companies should be aware of the pitfalls, says Hogan & Hartson Partner and FDA device specialist John Smith

510(k) Sponsors Should Be Wary Of Informal Talk With FDA, Attorney Says

Informal communications via telephone or e-mail before or during a 510(k) submission can be an efficient approach for sponsors, but companies should be aware of the pitfalls, says Hogan & Hartson Partner and FDA device specialist John Smith

Device Pre-Market Review Times Dropped In ’06 and ’07

FDA has been getting faster at reviewing device pre-market submissions during the past two years, according to the Office of Device Evaluation 2006-2007 annual report

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT025624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel